Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin

Hepatology

Volumn 28, Issue 2, 1998, Pages 555-561

  Terrault, Norah A ^a,b,c,e   Zhou, Shuan ^a,b,c   McCory, Robert W ^d   Pruett, Timothy L ^d   Lake, John R ^a,c   Roberts, John P ^a,c   Ascher, Nancy L ^a,c   Wright, Teresa L ^a,b,c  

^a Department of Medicine ^*

^b Veteran's Admin Medical Center

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ACTIVE IMMUNIZATION; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; GENE DELETION; GENE INSERTION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; DNA-DIRECTED DNA POLYMERASE; FEMALE; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; RECURRENCE; TIME FACTORS;

EID: 0031879292     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280237     Document Type: Article

References (22)

1. McGory R, Ishitani M, Oliveira W, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364.
2. Muller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, et al. Liver transplantation in HBs antigen (HBsAg) carriers: prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991;13:90-96.
3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
4. Terrault N, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. HEPATOLOGY 1996;24:1327-1333.
5. Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987;14:4051-4053.
6. Lake J. Should liver transplantation be performed for patients with chronic hepatitis B? Liver Transpl Surg 1995;1:260-265.
7. McMahon G, Ehrlich P, Moustafa Z, McCarthy LA, Dottave D, Tolpin MD, Nadler PI, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. HEPATOLOGY 1992;15:757-766.
8. Cariani E, Ravaggi A, Tanzi E, Romani L, Fiordalisi G, Bellati G, Caccamo L, et al. Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. J Med Virol 1995;47:410-415.
9. Carman W, Trautwein C, van Deursen F, Colman K, Dornan E, McIntyre G, Waters J, et al. Hepatitis B virus envelope variation after transplanta-tion with and without hepatitis B immune globulin prophylaxis. HEPATOLOGY 1996;24:489-493.
10. Hawkins A, Gilson R, Gilbert N, Wreghiu T, Gray J, Boa IA, Teder R, et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996;24:8-14.
11. Loeb D, Ganem D: Reverse transcription pathway of the hepatitis B virus. In: Skalpa A, Goff S, eds. Reverse Transcriptase. Cold Spring Harbor, NY, 1995:329-355.
12. Bartholomew M, Jansen R, Jeffers L, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:3-4.
13. Ling R, Mutimer D, Ahmed M, Boxall EH, Ellias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996;24:711-713.
14. Tipples G, Ma M, Fischer K, Bain V, Kneteman N, Tyrrell D. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro. HEPATOLOGY 1996;24:714-717.
15. McGory R, Ishitani M, Oliveira W, Stevenson W, McCullough C, Pruett T. Hepatitis B immune globulin dose requirements following orthotopic liver transplantation for chronic hepatitis B cirrhosis. Transplant Proc 1996;28:1687-1688.
16. Wallace LA, Carman WE Surface gene variation of HBV: scientific and medical relevance. Viral Hepatitis Reviews 1997;3:5-16.
17. Carman W, Zanetti A, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zucherman AJ, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-329.
18. Mangold C, Streeck R. Mutational analysis of the cysteine residues in the hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. J Virol 1993;67:4588-4597.
19. Mangold C, Unckell F, Werr M, Streeck R. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 1995;211:535-543.
20. Carman WE, Mimms LT. Pre-S/S gene variants of hepatitis B virus. In: Rizzetto M, Purcell RH, Gerin JL, Verme G. Viral Hepatitis and Liver Disease. Turino, Italy: Edizioni Minerva Medice, 1997:108-115.
21. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticosteroid responsive element. PNAS 1986;82:1627-1631.
22. Perrillo R, Rakela J, Martin P, Wright TL, Levy G, Schiff E, Dienstag J, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT). HEPATOLOGY 1997;26:260A.